Targeted DNA/RNA Sequencing Market

Market Overview:

The global targeted DNA/RNA sequencing market size reached US$ 12.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 43.7 Billion by 2032, exhibiting a growth rate (CAGR) of 15.39% during 2024-2032. The rising prevalence of chronic and infectious health diseases, the expanding adoption of NGS technologies, and ongoing technological advancements represent some of the key factors driving the market.

Targeted DNA/RNA sequencing is a precise and accurate method for sequencing specific genes or regions of interest in a sample. This technique enables researchers to identify and study variations in DNA or RNA associated with diseases or conditions. Targeted sequencing involves the selective amplification of specific genomic regions using polymerase chain reaction (PCR) or hybrid capture. PCR amplifies a specific region of interest using primers that match the target sequence, while hybrid capture studies the genomic areas of interest using complementary probes. Targeted sequencing has several advantages over whole-genome sequencing, including reduced costs, higher sequencing depth, and more efficient data analysis. Moreover, targeted sequencing is beneficial in analyzing samples with low DNA or RNA concentration, such as liquid biopsies. Targeted DNA/RNA sequencing finds a wide range of applications in medical research, including cancer diagnosis and treatment, pharmacogenomics, and prenatal genetic testing.

Targeted DNA/RNA Sequencing Market Trends:

The growing prevalence of chronic and infectious medical conditions, in confluence with ongoing technological advancements in the healthcare industry, represents the key factor driving the market growth. Besides this, due to the growing use of solvent biopsies in cancer diagnostics, the adoption of NGS technologies is exponentially increasing, which, in turn, is creating a favorable outlook for the market. These technologies utilize non-invasive cancer biomarkers, such as cell-free circulating tumor DNA (ctDNA), for real-time cancer detection and monitoring, which is further catalyzing the market demand. Moreover, the rise in genome mapping programs by scientists to analyze genes linked to the increasing prevalence of illnesses, such as diabetes, heart disease, asthma, cancer, and psychiatric disorders, and predict the onset of these diseases is acting as another significant growth-inducing factor. In addition to this, rapid innovations in the industry, such as the integration of cloud-computing systems for enhancing information management and reducing the costs of NGS systems, are presenting remunerative growth opportunities for the market. Concurrent with this, the expanding demand for non-invasive testing methods and the escalating demand for personalized medicine as it provides more accurate diagnosis and treatment options are fueling the market growth. Furthermore, extensive research and development (R&D) initiatives in exome sequencing, molecular biology, and technical engineering and increasing collaborations between public and private organizations for developing innovative products and technologies are positively impacting the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global targeted DNA/RNA sequencing market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on technology, workflow, application, type, and end user.

Technology Insights:

• NGS
• Others
   

The report has provided a detailed breakup and analysis of the targeted DNA/RNA sequencing market based on technology. This includes NSG and others. According to the report, NSG represented the largest segment.

Workflow Insights:

• Presequencing
• Sequencing
• Data Analysis
   

A detailed breakup and analysis of the targeted DNA/RNA sequencing market based on the workflow has also been provided in the report. This includes presequencing, sequencing, and data analysis. According to the report, sequencing accounted for the largest market share.

Application Insights:

• Human Biomedical Research
• Plant and Animal Sciences
• Drug Discovery
• Others
   

The report has provided a detailed breakup and analysis of the targeted DNA/RNA sequencing market based on the application. This includes human biomedical research, plant and animal sciences, drug discovery, and others. According to the report, drug discovery represented the largest segment.

Type Insights:

• DNA-based Targeted Sequencing
• RNA-based Targeted Sequencing
   

A detailed breakup and analysis of the targeted DNA/RNA sequencing market based on the type has also been provided in the report. This includes DNA- and RNA-based targeted sequencing. According to the report, DNA-based targeted sequencing accounted for the largest market share.

End User Insights:

• Hospitals & Clinics
• Academic & Research Institutes
• Pharma & Biotech Companies
   

The report has provided a detailed breakup and analysis of the targeted DNA/RNA sequencing market based on the end user. This includes hospitals & clinics, academic & research institutes, and pharma & biotech companies. According to the report, academic & research institutes represented the largest segment.

Regional Insights:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for targeted DNA/RNA sequencing. Some of the factors driving the North America targeted DNA/RNA sequencing market included the expanding prevalence of chronic diseases, the rising adoption of NGS technologies, and the growing demand for personalized medicines and therapies.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global targeted DNA/RNA sequencing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Agilent Technologies Inc., BGI Group, Dnastar Inc., Eurofins Genomics LLC (Eurofins Scientific SE), F. Hoffmann-La Roche Ltd, Illumina Inc., Integrated DNA Technologies, Inc. (Danaher Corporation), Macrogen Inc, Oxford Nanopore Technologies plc, PacBio, Pieriandx, QIAGEN N.V., Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Targeted DNA/RNA Sequencing Market Report Scope:

Key Questions Answered in This Report:

• How has the global targeted DNA/RNA sequencing market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global targeted DNA/RNA sequencing market?
• What is the impact of each driver, restraint, and opportunity on the global targeted DNA/RNA sequencing market?
• What are the key regional markets?
• Which countries represent the most attractive targeted DNA/RNA sequencing market?
• What is the breakup of the market based on technology?
• Which is the most attractive technology in the targeted DNA/RNA sequencing market?
• What is the breakup of the market based on workflow?
• Which is the most attractive workflow in the targeted DNA/RNA sequencing market?
• What is the breakup of the market based on application?
• Which is the most attractive application in the targeted DNA/RNA sequencing market?
• What is the breakup of the market based on type?
• Which is the most attractive type in the targeted DNA/RNA sequencing market?
• What is the breakup of the market based on end user?
• Which is the most attractive end user in the targeted DNA/RNA sequencing market?
• What is the competitive structure of the global targeted DNA/RNA sequencing market?
• Who are the key players/companies in the global targeted DNA/RNA sequencing market?

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the targeted DNA/RNA sequencing market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global targeted DNA/RNA sequencing market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the targeted DNA/RNA sequencing industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.